Loading…

Ghrelin receptor agonist (TZP‐101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis

Summary Background  TZP‐101 is a synthetic, selective ghrelin agonist in development for gastroparesis. Aim  To assess safety and effects of TZP‐101 in diabetes patients with symptomatic gastroparesis. Methods  Adults with type 1 or type 2 diabetes mellitus received placebo and TZP‐101 (80, 160, 320...

Full description

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2009-06, Vol.29 (11), p.1179-1187
Main Authors: EJSKJAER, N., VESTERGAARD, E. T., HELLSTRÖM, P. M., GORMSEN, L. C., MADSBAD, S., MADSEN, J. L., JENSEN, T. A., PEZZULLO, J. C., CHRISTIANSEN, J. S., SHAUGHNESSY, L., KOSUTIC, G.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background  TZP‐101 is a synthetic, selective ghrelin agonist in development for gastroparesis. Aim  To assess safety and effects of TZP‐101 in diabetes patients with symptomatic gastroparesis. Methods  Adults with type 1 or type 2 diabetes mellitus received placebo and TZP‐101 (80, 160, 320 or 600 μg/kg) infusions in a cross‐over manner following a radiolabelled meal. Blood glucose levels were stabilized using a hyperinsulinemic‐euglycemic clamp. Primary endpoints were gastric half emptying and latency times. Secondary measures included assessment of gastroparesis symptoms and endocrine responses. Results  Ten patients with type 1 (n = 7) or 2 (n = 3) diabetes, moderate‐to‐severe gastroparesis symptoms and ≥29% retention 4 h after a radiolabelled solid meal were enrolled. TZP‐101 produced significant reductions in solid meal half‐emptying (20%, P = 0.043) and latency (34%, P = 0.037) times vs. placebo. Reductions in overall postmeal symptom intensity (24%) and postprandial fullness (37%) following TZP‐101 infusion were not statistically significant. Most adverse events were mild and self‐limiting and there were no identifiable differences in numbers or types of adverse events between TZP‐101 and placebo. Conclusions  This proof‐of‐concept study demonstrates that the ghrelin agonist TZP‐101 is well‐tolerated in diabetes patients with moderate‐to‐severe chronic gastroparesis and shows statistically significant improvements in gastric emptying.
ISSN:0269-2813
1365-2036
1365-2036
DOI:10.1111/j.1365-2036.2009.03986.x